Skip to main content
Dale Schaar, MD, Oncology, New Brunswick, NJ, Robert Wood Johnson University Hospital

DaleGeoffreySchaarMDPhD

Oncology New Brunswick, NJ

Associate Professor of Medicine; Rutgers University-RWJMS; Hematologic Malignancies & Stem Cell Transplant; Rutgers Cancer Institute of New Jersey

Dr. Schaar is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schaar's full profile

Already have an account?

  • Office

    195 Little Albany Street - East Tower 9th Floor
    ET- 988
    New Brunswick, NJ 08903
    Phone(732) 235-4537
    Fax(732) 448-7887
  • Is this information wrong?

Education & Training

  • UMDNJ-Robert Wood Johnson Medical School
    UMDNJ-Robert Wood Johnson Medical SchoolFellowship, Hematology/Oncology, 1999 - 2003
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 1997 - 1999
  • Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical SchoolClass of 1997
  • University of Medicine and Dentistry of New Jersey/Rutgers UniversityPh.D., Microbiology (joint degree), 1991
  • Cook College, Rutgers UniversityB.A., Biochemistry, 1984

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1999 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Amgen Oncology Fellowship 2000
  • Predoctoral Fellowship New Jersey Commission on Cancer Research, 1988

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia  
    Barboza, N., Minakhina, S., Medina, D.J., Balsara, B., Greenwood, S., Huzzy, L., Rabson, A.B., Steward, R. and Schaar, D.G., Cancer Biol Ther, 6/1/2013
  • A Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome  
    Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M, Cancer, 4/1/2012
  • Accelerated R-COP: A Pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate  
    Levitt, M.J., Gharibo, M., Strair, R., Schaar, D., Rubin, A. and Bertino, J.R., J Chemotherapy, 1/1/2009
  • Join now to see all

Abstracts/Posters

  • Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution S...
    Dale Schaar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Dual-Specificity MAPK Phosphatases (DS-MKPs): novel targets for AML therapy.
    Schaar, D.G., Ting, Y. and Strair, R., Annual Workshop on Cancer Research in New Jersey, The New Jersey Commission on Cancer Research, 1/1/2006
  • Novel Strategies Targeting Pro-Survival Pathways in AML.
    Schaar, D.G., Liu, H., Sharma, S., Ting, Y., Martin, J., Krier, C., Ciardella, M., Osman, M., Goodell, L., Notterman, D.A. and Strair, R., Annual Workshop on Cancer Research in New Jersey, The New Jersey Commission on Cancer Research, 1/1/2005
  • Join now to see all

Other

  • The expression of a murine cytotoxic T-cell receptor and the lymphokine, interleukin-2, as a result of retrovirus-mediated gene transfer. Ph.D. Thesis. 
    Schaar, D.G.
    1/1/1991

Hospital Affiliations